The KEYNOTE-942 Phase III trial confirms the Phase IIb signal: adding the individualised neoantigen vaccine to pembrolizumab delivers a statistically significant improvement in recurrence-free survival versus pembrolizumab alone.

Clinical trials are the backbone of modern medicine, driving the development of new treatments, therapies, and medical technologies. In this category, we explore the latest advancements, trends, and insights shaping the world of clinical research. From early-phase studies to large-scale